OncoMatch/Clinical Trials/Lung Cancer — Non-Small Cell (NSCLC)
Lung Cancer — Non-Small Cell (NSCLC) Clinical Trials
OncoMatch filters Lung Cancer — Non-Small Cell (NSCLC) trials by the molecular markers that determine eligibility — EGFR, ALK, ROS1, KRAS, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout Lung Cancer — Non-Small Cell (NSCLC) trials
NSCLC has one of the broadest biomarker panels of any solid tumor for trial eligibility. Major driver mutations include EGFR, ALK, ROS1, KRAS, MET, BRAF, RET, the NTRK fusions, and HER2 / ERBB2. Immunotherapy-relevant markers include PD-L1, MMR, and MSI. IO resistance co-mutations (STK11 and KEAP1), the related RAS family (NRAS, HRAS), and tumor suppressor context (TP53, SMARCA4, RB1) commonly affect trial stratification. Your oncologist orders this from a tissue biopsy sample, or from blood (liquid biopsy) when fresh tissue isn't available.
EGFR and KRAS results often need more detail than a yes/no answer. Trials distinguish between sensitizing mutations (like EGFR L858R or exon 19 deletion), resistance mutations (T790M, C797S), and atypical mutations (G719X, exon 20 insertions). For KRAS, G12C is usually treated separately from G12D and other variants.
Recruiting trials fall into several distinct clusters. First-line targeted therapy trials for newly diagnosed metastatic disease, usually for patients with specific driver mutations. Second-line and later trials after progression on standard targeted agents. Perioperative immunotherapy trials in resectable disease, both before and after surgery. Combination trials in PD-L1 high disease. ADC trials are growing in post-IO settings. KRAS G12C trials make up their own active group. Phase 1 trials are common for patients with rare mutations or after multiple lines of therapy.
Common eligibility filters in NSCLC trials include several recurring features. Prior immunotherapy exposure: trials are usually IO-naïve, IO-pretreated, or post-IO progression specific. Prior targeted therapy lines, where the count and which agent matter. A patient who's been on a 3rd-generation EGFR inhibitor looks different to a trial than one who's been on a 1st-generation. STK11 or KEAP1 co-mutations gate IO eligibility on some trials because they're associated with IO resistance. CNS involvement, where many trials require treated, stable, or asymptomatic brain metastases, while others include or exclude leptomeningeal disease specifically. Autoimmune history, which often gates IO trials. ECOG of 0 or 1 is common, with some trials accepting ECOG 2.
Biomarkers tested in Lung Cancer — Non-Small Cell (NSCLC) trials
These are the molecular markers most commonly required or evaluated in Lung Cancer — Non-Small Cell (NSCLC) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
National Cancer Institute (NCI)
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
National Cancer Institute (NCI)
How OncoMatch finds Lung Cancer — Non-Small Cell (NSCLC) trials for you
AI reads the protocol
Every Lung Cancer — Non-Small Cell (NSCLC) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Lung Cancer — Non-Small Cell (NSCLC) and mark your biomarker results — EGFR, ALK, ROS1 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.